CN116836879A - Lactobacillus fermentum with colon cancer cell growth inhibition effect and application thereof - Google Patents
Lactobacillus fermentum with colon cancer cell growth inhibition effect and application thereof Download PDFInfo
- Publication number
- CN116836879A CN116836879A CN202310899300.7A CN202310899300A CN116836879A CN 116836879 A CN116836879 A CN 116836879A CN 202310899300 A CN202310899300 A CN 202310899300A CN 116836879 A CN116836879 A CN 116836879A
- Authority
- CN
- China
- Prior art keywords
- lactobacillus fermentum
- lactobacillus
- colon cancer
- strain
- fermentans
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000186840 Lactobacillus fermentum Species 0.000 title claims abstract description 92
- 229940012969 lactobacillus fermentum Drugs 0.000 title claims abstract description 92
- 206010009944 Colon cancer Diseases 0.000 title claims abstract description 55
- 208000029742 colonic neoplasm Diseases 0.000 title claims abstract description 52
- 230000000694 effects Effects 0.000 title abstract description 25
- 230000005764 inhibitory process Effects 0.000 title abstract description 17
- 230000010261 cell growth Effects 0.000 title abstract description 9
- 230000000968 intestinal effect Effects 0.000 claims abstract description 16
- 241000588724 Escherichia coli Species 0.000 claims abstract description 11
- 241000589517 Pseudomonas aeruginosa Species 0.000 claims abstract description 10
- 241000577483 Salmonella enterica subsp. enterica serovar Paratyphi B Species 0.000 claims abstract description 10
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 claims abstract description 10
- 241000607764 Shigella dysenteriae Species 0.000 claims abstract description 10
- 241000191967 Staphylococcus aureus Species 0.000 claims abstract description 10
- 229940007046 shigella dysenteriae Drugs 0.000 claims abstract description 10
- 235000013376 functional food Nutrition 0.000 claims abstract description 6
- 238000004519 manufacturing process Methods 0.000 claims abstract description 6
- 241001465754 Metazoa Species 0.000 claims abstract description 3
- 239000003963 antioxidant agent Substances 0.000 claims description 19
- 230000003078 antioxidant effect Effects 0.000 claims description 19
- 241000186660 Lactobacillus Species 0.000 claims description 17
- 229940039696 lactobacillus Drugs 0.000 claims description 17
- 230000002401 inhibitory effect Effects 0.000 claims description 14
- 239000003814 drug Substances 0.000 claims description 13
- 238000002360 preparation method Methods 0.000 claims description 8
- 229940079593 drug Drugs 0.000 claims description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
- 238000004321 preservation Methods 0.000 claims description 6
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims description 5
- 201000010099 disease Diseases 0.000 claims description 5
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 claims description 5
- 229960001756 oxaliplatin Drugs 0.000 claims description 5
- 229960002949 fluorouracil Drugs 0.000 claims description 4
- 238000009629 microbiological culture Methods 0.000 claims description 4
- 239000002671 adjuvant Substances 0.000 claims description 3
- 239000003560 cancer drug Substances 0.000 claims description 3
- 238000000855 fermentation Methods 0.000 abstract description 64
- 230000004151 fermentation Effects 0.000 abstract description 64
- 239000006228 supernatant Substances 0.000 abstract description 38
- 108090000623 proteins and genes Proteins 0.000 abstract description 34
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 abstract description 21
- 206010028980 Neoplasm Diseases 0.000 abstract description 19
- 201000011510 cancer Diseases 0.000 abstract description 13
- 230000006907 apoptotic process Effects 0.000 abstract description 12
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 abstract description 8
- 235000011389 fruit/vegetable juice Nutrition 0.000 abstract description 7
- 230000003064 anti-oxidating effect Effects 0.000 abstract description 6
- 239000002246 antineoplastic agent Substances 0.000 abstract description 6
- 229940041181 antineoplastic drug Drugs 0.000 abstract description 6
- 239000003242 anti bacterial agent Substances 0.000 abstract description 5
- 229940088710 antibiotic agent Drugs 0.000 abstract description 5
- 230000003115 biocidal effect Effects 0.000 abstract description 4
- 210000004369 blood Anatomy 0.000 abstract description 4
- 239000008280 blood Substances 0.000 abstract description 4
- 230000000529 probiotic effect Effects 0.000 abstract description 3
- 206010018910 Haemolysis Diseases 0.000 abstract description 2
- 230000008588 hemolysis Effects 0.000 abstract description 2
- 210000002784 stomach Anatomy 0.000 abstract description 2
- 238000003501 co-culture Methods 0.000 abstract 1
- 230000001988 toxicity Effects 0.000 abstract 1
- 231100000419 toxicity Toxicity 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 70
- 102000004169 proteins and genes Human genes 0.000 description 26
- 235000018102 proteins Nutrition 0.000 description 24
- 230000001580 bacterial effect Effects 0.000 description 22
- 108060000903 Beta-catenin Proteins 0.000 description 19
- 102000015735 Beta-catenin Human genes 0.000 description 19
- 239000007788 liquid Substances 0.000 description 18
- 235000006708 antioxidants Nutrition 0.000 description 17
- 239000002609 medium Substances 0.000 description 17
- -1 hydroxyl radicals Chemical class 0.000 description 15
- 229920001817 Agar Polymers 0.000 description 13
- 239000008272 agar Substances 0.000 description 13
- 239000001963 growth medium Substances 0.000 description 13
- 238000000034 method Methods 0.000 description 12
- 150000003254 radicals Chemical class 0.000 description 12
- 230000012010 growth Effects 0.000 description 11
- 241000894006 Bacteria Species 0.000 description 10
- 238000012258 culturing Methods 0.000 description 10
- 238000005259 measurement Methods 0.000 description 9
- 150000004666 short chain fatty acids Chemical class 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- 238000002835 absorbance Methods 0.000 description 8
- 244000052616 bacterial pathogen Species 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- 238000004113 cell culture Methods 0.000 description 7
- MGJZITXUQXWAKY-UHFFFAOYSA-N diphenyl-(2,4,6-trinitrophenyl)iminoazanium Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1N=[N+](C=1C=CC=CC=1)C1=CC=CC=C1 MGJZITXUQXWAKY-UHFFFAOYSA-N 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 230000002292 Radical scavenging effect Effects 0.000 description 6
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- 230000029087 digestion Effects 0.000 description 6
- 210000001035 gastrointestinal tract Anatomy 0.000 description 6
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 235000021391 short chain fatty acids Nutrition 0.000 description 6
- 238000009631 Broth culture Methods 0.000 description 5
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 5
- 102100026539 Induced myeloid leukemia cell differentiation protein Mcl-1 Human genes 0.000 description 5
- GLEVLJDDWXEYCO-UHFFFAOYSA-N Trolox Chemical compound O1C(C)(C(O)=O)CCC2=C1C(C)=C(C)C(O)=C2C GLEVLJDDWXEYCO-UHFFFAOYSA-N 0.000 description 5
- 239000000427 antigen Substances 0.000 description 5
- 108091007433 antigens Proteins 0.000 description 5
- 102000036639 antigens Human genes 0.000 description 5
- 239000012530 fluid Substances 0.000 description 5
- 230000002496 gastric effect Effects 0.000 description 5
- 230000002949 hemolytic effect Effects 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 230000000861 pro-apoptotic effect Effects 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 101100447432 Danio rerio gapdh-2 gene Proteins 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- 101150112014 Gapdh gene Proteins 0.000 description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- 102000013814 Wnt Human genes 0.000 description 4
- 108050003627 Wnt Proteins 0.000 description 4
- 230000003213 activating effect Effects 0.000 description 4
- 230000021164 cell adhesion Effects 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 230000003211 malignant effect Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 108020004465 16S ribosomal RNA Proteins 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 101001056180 Homo sapiens Induced myeloid leukemia cell differentiation protein Mcl-1 Proteins 0.000 description 3
- 206010027476 Metastases Diseases 0.000 description 3
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000032683 aging Effects 0.000 description 3
- 230000004900 autophagic degradation Effects 0.000 description 3
- GWYFCOCPABKNJV-UHFFFAOYSA-N beta-methyl-butyric acid Natural products CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 description 3
- 238000010609 cell counting kit-8 assay Methods 0.000 description 3
- 230000000875 corresponding effect Effects 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 3
- 239000004310 lactic acid Substances 0.000 description 3
- 235000014655 lactic acid Nutrition 0.000 description 3
- 101150094281 mcl1 gene Proteins 0.000 description 3
- 230000009401 metastasis Effects 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 230000001590 oxidative effect Effects 0.000 description 3
- 238000004445 quantitative analysis Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- XYHKNCXZYYTLRG-UHFFFAOYSA-N 1h-imidazole-2-carbaldehyde Chemical compound O=CC1=NC=CN1 XYHKNCXZYYTLRG-UHFFFAOYSA-N 0.000 description 2
- WLAMNBDJUVNPJU-UHFFFAOYSA-N 2-methylbutyric acid Chemical compound CCC(C)C(O)=O WLAMNBDJUVNPJU-UHFFFAOYSA-N 0.000 description 2
- GWYFCOCPABKNJV-UHFFFAOYSA-M 3-Methylbutanoic acid Natural products CC(C)CC([O-])=O GWYFCOCPABKNJV-UHFFFAOYSA-M 0.000 description 2
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 2
- 101100029855 Arabidopsis thaliana PIP1.4 gene Proteins 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 102000011727 Caspases Human genes 0.000 description 2
- 108010076667 Caspases Proteins 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- 108020005199 Dehydrogenases Proteins 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 102000043276 Oncogene Human genes 0.000 description 2
- 108010019160 Pancreatin Proteins 0.000 description 2
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 2
- 108010090931 Proto-Oncogene Proteins c-bcl-2 Proteins 0.000 description 2
- 102000013535 Proto-Oncogene Proteins c-bcl-2 Human genes 0.000 description 2
- 108010087230 Sincalide Proteins 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- 230000035508 accumulation Effects 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 230000003698 anagen phase Effects 0.000 description 2
- 238000003149 assay kit Methods 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 235000015278 beef Nutrition 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 229940041514 candida albicans extract Drugs 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 229960004316 cisplatin Drugs 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 238000004737 colorimetric analysis Methods 0.000 description 2
- 231100000599 cytotoxic agent Toxicity 0.000 description 2
- 239000002619 cytotoxin Substances 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 2
- 239000012154 double-distilled water Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 235000021107 fermented food Nutrition 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000012737 fresh medium Substances 0.000 description 2
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000013632 homeostatic process Effects 0.000 description 2
- TUJKJAMUKRIRHC-UHFFFAOYSA-N hydroxyl Chemical compound [OH] TUJKJAMUKRIRHC-UHFFFAOYSA-N 0.000 description 2
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 2
- 238000009630 liquid culture Methods 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 235000019341 magnesium sulphate Nutrition 0.000 description 2
- 229940099596 manganese sulfate Drugs 0.000 description 2
- 235000007079 manganese sulphate Nutrition 0.000 description 2
- 239000011702 manganese sulphate Substances 0.000 description 2
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 239000006916 nutrient agar Substances 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 229940055695 pancreatin Drugs 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
- YNPNZTXNASCQKK-UHFFFAOYSA-N phenanthrene Chemical compound C1=CC=C2C3=CC=CC=C3C=CC2=C1 YNPNZTXNASCQKK-UHFFFAOYSA-N 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 239000006041 probiotic Substances 0.000 description 2
- 235000018291 probiotics Nutrition 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 238000004088 simulation Methods 0.000 description 2
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- VSIVTUIKYVGDCX-UHFFFAOYSA-M sodium;4-[2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)tetrazol-2-ium-5-yl]benzene-1,3-disulfonate Chemical compound [Na+].COC1=CC([N+]([O-])=O)=CC=C1[N+]1=NC(C=2C(=CC(=CC=2)S([O-])(=O)=O)S([O-])(=O)=O)=NN1C1=CC=C([N+]([O-])=O)C=C1 VSIVTUIKYVGDCX-UHFFFAOYSA-M 0.000 description 2
- 125000003831 tetrazolyl group Chemical group 0.000 description 2
- 238000010257 thawing Methods 0.000 description 2
- UAXOELSVPTZZQG-UHFFFAOYSA-N tiglic acid Natural products CC(C)=C(C)C(O)=O UAXOELSVPTZZQG-UHFFFAOYSA-N 0.000 description 2
- YWYZEGXAUVWDED-UHFFFAOYSA-N triammonium citrate Chemical compound [NH4+].[NH4+].[NH4+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O YWYZEGXAUVWDED-UHFFFAOYSA-N 0.000 description 2
- 239000001393 triammonium citrate Substances 0.000 description 2
- 235000011046 triammonium citrate Nutrition 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- 239000012224 working solution Substances 0.000 description 2
- 239000012138 yeast extract Substances 0.000 description 2
- UOHPEWIBMAQKCN-UHFFFAOYSA-N 1,3,5,5,6-pentafluoro-1,3-diazinane-2,4-dione Chemical compound FC1C(C(N(C(N1F)=O)F)=O)(F)F UOHPEWIBMAQKCN-UHFFFAOYSA-N 0.000 description 1
- OXQGTIUCKGYOAA-UHFFFAOYSA-N 2-Ethylbutanoic acid Chemical compound CCC(CC)C(O)=O OXQGTIUCKGYOAA-UHFFFAOYSA-N 0.000 description 1
- XTWYTFMLZFPYCI-KQYNXXCUSA-N 5'-adenylphosphoric acid Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XTWYTFMLZFPYCI-KQYNXXCUSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 229940088872 Apoptosis inhibitor Drugs 0.000 description 1
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 1
- 102000007347 Apyrase Human genes 0.000 description 1
- 108010007730 Apyrase Proteins 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 208000004736 B-Cell Leukemia Diseases 0.000 description 1
- 208000003950 B-cell lymphoma Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 102000051485 Bcl-2 family Human genes 0.000 description 1
- 108700038897 Bcl-2 family Proteins 0.000 description 1
- 235000010149 Brassica rapa subsp chinensis Nutrition 0.000 description 1
- 235000000536 Brassica rapa subsp pekinensis Nutrition 0.000 description 1
- 241000499436 Brassica rapa subsp. pekinensis Species 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- LDGSLZWFCMSKMW-UHFFFAOYSA-N CC(C(=O)O)CC.CC(CC(=O)O)C.C(C)(=O)O Chemical compound CC(C(=O)O)CC.CC(CC(=O)O)C.C(C)(=O)O LDGSLZWFCMSKMW-UHFFFAOYSA-N 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 108010076119 Caseins Proteins 0.000 description 1
- 102000011632 Caseins Human genes 0.000 description 1
- 102000003952 Caspase 3 Human genes 0.000 description 1
- 108090000397 Caspase 3 Proteins 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 108010067225 Cell Adhesion Molecules Proteins 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000011724 DNA Repair Enzymes Human genes 0.000 description 1
- 108010076525 DNA Repair Enzymes Proteins 0.000 description 1
- 230000005971 DNA damage repair Effects 0.000 description 1
- 238000007400 DNA extraction Methods 0.000 description 1
- 208000035240 Disease Resistance Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000033962 Fontaine progeroid syndrome Diseases 0.000 description 1
- 229940123457 Free radical scavenger Drugs 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 101710088172 HTH-type transcriptional regulator RipA Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 244000199866 Lactobacillus casei Species 0.000 description 1
- 235000013958 Lactobacillus casei Nutrition 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 241000191996 Pediococcus pentosaceus Species 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 102000012338 Poly(ADP-ribose) Polymerases Human genes 0.000 description 1
- 108010061844 Poly(ADP-ribose) Polymerases Proteins 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 241000295644 Staphylococcaceae Species 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 108010093894 Xanthine oxidase Proteins 0.000 description 1
- 102100033220 Xanthine oxidase Human genes 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 229960003022 amoxicillin Drugs 0.000 description 1
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 230000002424 anti-apoptotic effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000000158 apoptosis inhibitor Substances 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000003833 bile salt Substances 0.000 description 1
- 229940093761 bile salts Drugs 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 239000012159 carrier gas Substances 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 102000008395 cell adhesion mediator activity proteins Human genes 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 229940099352 cholate Drugs 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
- 229960002626 clarithromycin Drugs 0.000 description 1
- AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 230000007760 free radical scavenging Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000005350 fused silica glass Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 231100000024 genotoxic Toxicity 0.000 description 1
- 230000001738 genotoxic effect Effects 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 239000001307 helium Substances 0.000 description 1
- 229910052734 helium Inorganic materials 0.000 description 1
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940099472 immunoglobulin a Drugs 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000010813 internal standard method Methods 0.000 description 1
- 244000000074 intestinal pathogen Species 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229940017800 lactobacillus casei Drugs 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 239000002068 microbial inoculum Substances 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 208000025113 myeloid leukemia Diseases 0.000 description 1
- 230000004942 nuclear accumulation Effects 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 231100000590 oncogenic Toxicity 0.000 description 1
- 230000002246 oncogenic effect Effects 0.000 description 1
- 108091008819 oncoproteins Proteins 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 238000006395 oxidase reaction Methods 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 230000008855 peristalsis Effects 0.000 description 1
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000000751 protein extraction Methods 0.000 description 1
- 238000004080 punching Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 238000010814 radioimmunoprecipitation assay Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000022983 regulation of cell cycle Effects 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000027756 respiratory electron transport chain Effects 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- SWGJCIMEBVHMTA-UHFFFAOYSA-K trisodium;6-oxido-4-sulfo-5-[(4-sulfonatonaphthalen-1-yl)diazenyl]naphthalene-2-sulfonate Chemical compound [Na+].[Na+].[Na+].C1=CC=C2C(N=NC3=C4C(=CC(=CC4=CC=C3O)S([O-])(=O)=O)S([O-])(=O)=O)=CC=C(S([O-])(=O)=O)C2=C1 SWGJCIMEBVHMTA-UHFFFAOYSA-K 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 108010050327 trypticase-soy broth Proteins 0.000 description 1
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 229940075420 xanthine Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/225—Lactobacillus
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
The invention discloses a lactobacillus fermentum with a colon cancer cell growth inhibition effect and application thereof, wherein the lactobacillus fermentum has stronger adhesion capability to human colon cancer cells, and fermentation supernatant and colon cancer cells HCT-116 after co-culture show stronger cancer cell growth inhibition activity and cancer cell apoptosis promotion capability, and can greatly enhance the toxicity to cancer cells when being used together with anticancer drugs; the strain has good safety, does not generate hemolysis phenomenon on Columbia blood plates, is sensitive to various common antibiotics, does not carry antibiotic resistance genes, and has better tolerance to artificial stomach and intestinal juice; meanwhile, the strain has strong acetic acid and butyric acid production capability, and fermentation liquor has strong inhibition capability and strong antioxidation effect on escherichia coli, pseudomonas aeruginosa, staphylococcus aureus, salmonella typhimurium, salmonella paratyphi b, shigella dysenteriae and the like. Therefore, the strain has obvious probiotic effect and can be applied to the field of functional foods for human and animals.
Description
Technical Field
The invention belongs to the technical field of microorganisms, and particularly relates to lactobacillus fermentum with a strong inhibition effect on colon cancer cells and various intestinal pathogenic bacteria.
Background
Lactobacillus fermentum (Lactobacillus fermentum) belongs to the genus Lactobacillus. Research shows that the strain can produce lactic acid and other short chain fatty acids, reduce pH value in intestinal tract, increase the number of beneficial bacteria in intestinal tract, inhibit growth of harmful bacteria, maintain acid-base balance in intestinal tract, and promote intestinal tract health. The strain can promote immunoglobulin production, increase leukocyte quantity, and improve disease resistance of organism. Lactobacillus fermentum can decompose complex carbohydrates, proteins and fats in food, and promote digestion and absorption of food. In addition, the lactobacillus fermentum can promote intestinal peristalsis, increase the volume and the moisture of excrement and relieve the symptoms of dyspepsia such as constipation and the like.
Disclosure of Invention
Aiming at the defects in the prior art, the invention provides lactobacillus fermentum with the effect of inhibiting the growth of colon cancer cells and application thereof, and the lactobacillus fermentum has the effects of inhibiting the growth of colon cancer cells, inhibiting bacteria, resisting inflammation, producing acid, reducing blood sugar and improving the adaptability of human intestinal environment.
In order to achieve the above purpose, the technical scheme adopted by the invention for solving the technical problems is as follows:
a strain of lactobacillus fermentum (Lactobacillus fermentans) GS1108 is preserved in China general microbiological culture Collection center (CGMCC) with the preservation number of 27395 in the year 2023 and the month 5 and the day 22.
The lactobacillus fermentum GS1108 is applied to the preparation of anti-colon cancer drugs or anti-colon cancer auxiliary drugs.
Application of lactobacillus fermentum GS1108 in inhibiting escherichia coli, pseudomonas aeruginosa, staphylococcus aureus, salmonella typhimurium, salmonella paratyphi B or shigella dysenteriae for non-disease treatment purpose.
The application of the lactobacillus fermentum GS1108 in preparing medicaments for treating diseases caused by escherichia coli, pseudomonas aeruginosa, staphylococcus aureus, salmonella typhimurium, salmonella paratyphi B or shigella dysenteriae.
Use of lactobacillus fermentum GS1108 as described above in functional food for modulating the intestinal flora of humans or animals.
An anti-colon cancer drug or an anti-colon cancer adjuvant drug comprising lactobacillus fermentum GS1108 as described above.
An antioxidant drug comprising lactobacillus fermentum GS1108 as described above.
A functional food comprising lactobacillus fermentum GS1108 as described above.
Use of lactobacillus fermentum (Lactobacillus fermentans) GS1108 in combination with 5-fluorouracil or oxaliplatin for the preparation of a medicament for treating colon cancer.
The lactobacillus fermentum GS1108 is obtained by separating and screening from Guizhou fermented food. Lactobacillus fermentum GS1108 grows well on MRS agar medium, and the colony is milky white, smooth in surface, neat in edge, opaque, and has a purple and rod-shaped gram stain by microscopic examination of the bacterial form. The total genome DNA of the bacterial strain is amplified by PCR by adopting 27F/1492R of bacterial universal primer 16S rRNA as a template, the gene sequence obtained by sequencing is input into NCBI database for comparison, the similarity rate of the gene sequence with a standard strain Lactobacillus fermentans strain TMPC F335 in GenBank reaches 98.53%, and the strain can be initially identified as lactobacillus fermentum (Lactobacillus fermentans).
The lactobacillus fermentum GS1108 strain has good safety, does not generate hemolysis phenomenon on a Columbia blood plate, is sensitive to various common antibiotics, and does not carry antibiotic resistance genes;
the lactobacillus fermentum GS1108 strain has strong intestinal tract adaptability and better tolerance to artificial stomach and intestinal juice;
the lactobacillus fermentum GS1108 strain has obvious probiotics performance, has stronger adhesion capability to human colon cancer cells, has stronger cancer cell activity inhibition capability after the fermentation supernatant and colon cancer cells HCT-116 are co-cultivated, has stronger inhibition capability to escherichia coli, pseudomonas aeruginosa, staphylococcus aureus, salmonella typhimurium, salmonella paratyphi B, shigella dysenteriae and the like, can generate various short-chain fatty acids such as acetic acid, butyric acid and the like, and has stronger antioxidation effect.
The beneficial effects of the invention are as follows:
1. the lactobacillus fermentum GS1108 provided by the invention is separated and screened from Guizhou pickled Chinese cabbage, grows well on an MRS agar medium, and has good tolerance to acid and bile salts.
2. The lactobacillus fermentum GS1108 provided by the invention has good adhesion capability to human colon cancer cells and has stronger cancer cell activity inhibition capability.
3. The lactobacillus fermentum GS1108 provided by the invention has strong bacteriostasis to common intestinal pathogenic bacteria such as escherichia coli, pseudomonas aeruginosa, staphylococcus aureus, salmonella typhimurium, salmonella paratyphi B, shigella dysenteriae and the like.
4. The lactobacillus fermentum GS1108 provided by the invention can produce various short-chain fatty acids such as acetic acid, butyric acid and the like, and has strong antioxidation.
Preservation information:
lactobacillus fermentum (Lactobacillus fermentans) GS1108 is preserved in China general microbiological culture Collection center (CGMCC) with the preservation number of 27395, which is No.1 and No. 3 in North Xili road, korean, beijing, 5 months, 22 days in 2023
Drawings
FIG. 1 is a diagram showing the phylogenetic relationship between Lactobacillus fermentum GS1108 and other strains according to the present invention;
FIG. 2 shows the inhibition of colon cancer cell growth at various concentrations of fermentation supernatant of Lactobacillus fermentum GS 1108; in the figure, A is control, B is fermentation supernatant (1%), C is fermentation supernatant (1%) +cisplatin (DDP) 20. Mu.M, D is fermentation supernatant (1%) +oxaliplatin (Oxaliptin) 20. Mu.M), E is fermentation supernatant (1%) +5-fluorouracil (5 fu) 20. Mu.M.
FIG. 3 is a GC-MS detection ion flow diagram of short chain fatty acid of fermentation supernatant of lactobacillus fermentum GS1108.
Detailed Description
The present invention will be described in further detail with reference to the following examples in order to make the objects, technical solutions and advantages of the present invention more apparent. It should be understood that the particular embodiments described herein are illustrative only and are not intended to limit the invention, i.e., the embodiments described are merely some, but not all, of the embodiments of the invention.
Thus, the following detailed description of the embodiments of the invention, as provided, is not intended to limit the scope of the invention, as claimed, but is merely representative of selected embodiments of the invention. All other embodiments, which can be made by a person skilled in the art without making any inventive effort, are intended to be within the scope of the present invention.
It is noted that relational terms such as "first" and "second", and the like, are used solely to distinguish one entity or action from another entity or action without necessarily requiring or implying any actual such relationship or order between such entities or actions. Moreover, the terms "comprises," "comprising," or any other variation thereof, are intended to cover a non-exclusive inclusion, such that a process, method, article, or apparatus that comprises a list of elements does not include only those elements but may include other elements not expressly listed or inherent to such process, method, article, or apparatus. Without further limitation, an element defined by the phrase "comprising one … …" does not exclude the presence of other like elements in a process, method, article, or apparatus that comprises an element.
The features and capabilities of the present invention are described in further detail below with reference to the examples and figures.
Example 1 isolation, screening and molecular biological identification of lactobacillus fermentum GS 1108:
1. material preparation
The strain is derived from Guizhou fermented food;
the 16S rRNA universal primers 27F and 1492R were synthesized by biological engineering (Shanghai) Inc., and the sequences were as follows:
27F:5-AGAGTTTGATCMTGGCTCAG-3,
1492R:5-GGTTACCTTGTTACGACTT-3
formulation of MRS broth (per liter): 10.0g of casein enzyme digest, 10.0g of beef extract powder, 4.0g of yeast extract powder, 2.0g of tri-ammonium citrate, 5.0g of sodium acetate, 0.2g of magnesium sulfate, 0.05g of manganese sulfate, 2.0g of dipotassium hydrogen phosphate, 20.0g of glucose, tween-80 and a final pH of about 5.7.
Formulation of MRS agar Medium (per liter): 10.0g of peptone, 5.0g of beef extract powder, 4.0g of yeast extract powder, 20.0g of glucose, 1.0mL of tween 80, 2.0g of dipotassium hydrogen phosphate, 5.0g of sodium acetate, 2.0g of tri-ammonium citrate, 0.2g of magnesium sulfate, 0.05g of manganese sulfate, 15.0g of agar and a final pH of about 6.2.
2. Detailed description of the preferred embodiments
1mL of the sample is taken in 20mLMRS broth, fully and uniformly mixed by shaking, and placed in a shaking table at a constant temperature of 37 ℃ for 24 hours. 10-fold gradient dilution is adopted, the culture is spread and inoculated on MRS agar culture medium, single colony is picked after 24h culture at 37 ℃, and single colony purification is carried out continuously for 3 times. The purified strain is inoculated into 600 mu L of MRS broth culture medium, shake-cultured for 18h at 37 ℃, 400 mu L of 50% (V/V) sterile glycerol is added, and the strain is frozen in an ultralow temperature refrigerator at-80 ℃ for standby. After the purified strain is amplified and cultivated by MRS broth, the strain DNA is extracted by adopting a Tiangen bacterial genome DNA extraction kit, the 16S rRNA amplification is finished by adopting a colony PCR technology, the sequencing of PCR products is finished by a biological engineering (Shanghai) limited company, the nucleotide sequence is shown as SEQ ID No.1, the sequence is compared with BLAST in NCBI, the similarity of one strain with a standard strain Lactobacillusfermentans strain TMPC F335 reaches 98.53%, the strain can be initially identified as lactobacillus fermentum (Lactobacillus fermentans), the strain is named as GS1108, and the phylogenetic relationship between the strain and other strains is shown as figure 1. Lactobacillus fermentum GS1108 was gram stained using the kit method, and the stained bacterial morphology was observed and recorded under a microscope. The lactobacillus fermentum GS1108 grows well on an MRS agar culture medium, the colony shape is milky white, round convex, smooth in edge and smooth in surface, and after dyeing, the thallus is rod-shaped and purple in microscopic examination, so that the bacterial colony meets the morphological characteristics of the lactobacillus fermentum. The strain is preserved in China general microbiological culture Collection center (CGMCC) at 22 days of 5 months of 2023, and the preservation number is 27395.
Example 2 growth-inhibiting and apoptosis-promoting effects of Lactobacillus fermentum GS1108 fermentation broth on colon cancer cells
2.1 adhesion of Lactobacillus fermentum GS1108 to human colon cancer cells
The lactobacillus fermentum GS1108 frozen strain is inoculated into MRS broth culture medium after resuscitating and culturing, and is cultured at the constant temperature of 37 ℃ for 24 hours. After the cultivation, the mixture is centrifuged for 10min at-4 ℃ and 5000r/min, and washed with sterile PBS buffer solution for a plurality of times. Adjusting the concentration of the bacterial suspension to 1X 10 6 CFU/mL for later use. Resuscitates human colon cancer cells HT-29, inoculates them into six well cell culture dishes, adds DMEM complete medium and places them in 5% CO at 37 deg.C 2 Medium culture, and medium culture is replaced once in two days. When the cell attachment state reached 80%, digestion was performed using 0.25% pancreatin-EDTA, and subcultured. After the completion of the culture, the cells were counted by a cell counting plate and the cell concentration was adjusted to 5X 10 6 And each mL. 1mL of the cell suspension was added to one of the culture wells of a six-well cell culture dish and placed in an incubator for culture. Cells in the plates were grown to a monolayer, DMEM medium was discarded and each well was rinsed 3 times with sterile PBS. 1mL of the prepared bacterial suspension is added into a cell hole, a cell culture plate is slightly rocked, a small amount of bacterial liquid in the hole is sucked for plate counting, and the result is taken as the initial viable count in the bacterial suspension. The cell plates were incubated at 37℃for 2h, the medium was discarded and washed 3 times with sterile PBS buffer. The cells were digested with 0.7mL of 0.25% trypsin-EDTA for 10min, and after the cells were completely detached, the digestion was terminated by adding 0.3mL of DMEM culture solution, and the culture solution after the end of the adhesion experiment was collected for plate counting, and the result was used as the number of adhesion viable bacteria. Adhesion (%) = number of lactic acid bacteria at end period/number of initial lactic acid bacteria inoculation x 100%
The results are shown in Table 1. As a result, it was found that the adhesion rate of Lactobacillus fermentum GS1108 to human colon cancer cell HCT116 was 35.41%.
TABLE 1 adhesion Rate of Lactobacillus fermentum GS1108 to human colon cancer cells HCT (%)
2.2 growth inhibition of colon cancer cells by Lactobacillus fermentum GS1108 fermentation supernatant
Preparation of fermentation supernatant of lactobacillus fermentum GS 1108: resuscitating lactobacillus fermentum GS1108, inoculating into MRS broth, and culturing at 37deg.C for 24 hr to obtain bacterial suspension with concentration of 1×10 9 CFU/mL. Centrifuging at-4deg.C and 5000r/min for 10min after culturing, collecting fermentation supernatant, and filtering with bacterial filter membrane.
Recovery of cancer cells: pre-heated DMEM medium containing 10% fbs and 1% diabody was prepared in 15mL centrifuge tubes, placed on a sterile operating table, and frozen human colon cancer cells (HCT 116) were removed from-80 ℃ refrigerator or liquid nitrogen in a 37 ℃ water bath for rapid thawing. After thawing the cells, they were transferred on a sterile operating table to a prepared 15mL centrifuge tube containing the medium, centrifuged at 1000r/min for 3min to resuspend the cells, aspirated into a 6cm cell culture dish, and incubated in 5% CO 2 After 24h incubation at 37℃in the incubator, fresh medium was changed.
Cell passage: and when the cell growth state is good and the density reaches about 80 percent, carrying out passage. After the medium and sterile PBS were preheated in a 37℃water bath, old medium in the cell culture dish was aspirated off on a sterile operating table, cells were washed with preheated PBS to remove dead cells and residual medium, cells were digested with 0.25% pancreatin, pancreatin was aspirated off with a pipette after the cells became round, the digestion was stopped, and cells were collected in a sterile centrifuge tube. The supernatant was aspirated off by centrifugation at 1000r/min for 3min, and the cells were resuspended in fresh medium and then aspirated into fresh cell culture dishes and placed in a cell incubator for culture.
Cytotoxicity experiment: the influence of fermentation supernatant of lactobacillus fermentum GS1108 on the growth of colon cancer cells is determined by using a CCK-8 kit (Cell Counting Kit-8 cell counting reagent), wherein the kit uses tetrazolium salt WST-8 with high water solubility, the tetrazolium salt WST-8 can be reduced by some dehydrogenases in mitochondria to generate yellow formazan under the condition of existence of an electronic coupling reagent, the amount of formazan generated by the dehydrogenases and the number of living cells are in a direct linear relation, the more and faster the proliferation of cancer cells, the darker the color, the more toxic to the cancer cells, the lighter the color, the high sensitivity of the method and the simplicity and convenience in operation are realized. HCT116 cells in the logarithmic growth phase were evenly spread into 96-well plates after digestion and centrifugation, and the count ensured 2000 cells per well. Culturing for 12 hours, adding 1% of prepared probiotic fermentation liquor after cell adhesion is stable, and simultaneously adding three anticancer drugs respectively: pentafluorouracil (5 fu), oxaliplatin (Oxaliptin) and cisplatin (DDP) were each 20 μm in final concentration, 5 replicates were set for each treatment, and after 48 hours of incubation, CCK-8 kit detection was performed, and incubation was continued in a cell incubator for 1 hour, and absorbance was measured with a microplate reader at 450 nm. Meanwhile, no fermentation broth and anticancer drug control were set.
The measurement results are shown in Table 2. The fermentation supernatant of 1% lactobacillus fermentum GS1108 shows obvious inhibition effect on the growth of human colon cancer cells, and the colon cancer cell density after 48 hours of culture is 73.87% of that of a control. The effect was most pronounced when 1% of the fermentation supernatant was used in combination with the anticancer drug 5-fluorouracil (5 fu, 20. Mu.M) or Oxaliplatin (20. Mu.M), and the colon cancer cell densities after 48h of culture were 37.86% and 47.95% of the control, respectively. It was demonstrated that lactobacillus casei GS1108 fermentation supernatant alone or in combination with anticancer drugs had significant inhibitory effect on human colon cancer cell growth (figure 2).
TABLE 2 influence of GS1108 fermentation supernatants on colon cancer cell growth in combination with several anticancer drugs
Pro-apoptotic effects of 2.3GS1108 fermentation supernatants on human colon cancer cells
2.3.1 materials and methods
Cell culture: HCT116 cells in the logarithmic growth phase were evenly spread into 96-well plates after digestion and centrifugation, and the count ensured 2000 cells per well. After 12 hours of culture, GS0605 fermentation supernatant is added for 1% after cell attachment is stabilized, 5 replicates are set for each treatment, and protein is extracted after 48 hours of culture.
Protein extraction: after washing the cultured cells twice with PBS, all remaining PBS on the cell surface was aspirated as much as possible. Cells were placed in an ice bath, RIPA lysate containing the protease inhibitor Cocktail (protease inhibitor diluted 1:100) was added, and the whole cells were scraped into a 1.5ml sterile centrifuge tube and placed in an ice bath for 30min. Centrifuging at 12000r/min and 4 ℃ for 10min, and collecting supernatant into a new 1.5ml sterile centrifuge tube to obtain the extracted protein sample. The protein sample can be directly subjected to protein quantitative analysis or stored in a refrigerator at-80 ℃ for standby. For the protein sample after quantitative analysis, protein buffer solution can be added, and the protein sample is placed in a metal bath and boiled at 98 ℃ for 10min to denature the protein, and the protein sample is stored in a refrigerator at-20 ℃ for standby after instantaneous centrifugation.
Protein quantification: and (5) carrying out quantitative analysis by using the Biyundin protein quantitative kit. Protein samples were diluted 20-fold and added to labeled 96-well plates. Preparing BCA working solution according to the ratio of BCA reagent A to BCA reagent B of 50:1, fully and uniformly mixing, adding 200 μl of BCA working solution into each hole, shaking and uniformly mixing for 30s, covering each sample hole, and placing in a constant temperature incubator at 37 ℃ for 30min. The absorbance at 562nm was measured, the protein concentration of each sample was read out in a linear range of the standard curve based on the corrected absorbance for each protein sample, and the amount of protein in the original sample was calculated based on the sample volume and dilution.
2.3.2 experimental results
(1) Effect of GS1108 fermentation supernatant on cell adhesion factor beta-catenin
Cancer cell spread is characterized by disordered interactions between cells and cell adhesion. Beta-catenin (beta-catenin) is a multifunctional protein, is an important cell adhesion molecule, participates in cell growth and repair, and plays an important role in the processes of tumorigenesis and metastasis. The postoperative recurrence rate of colorectal cancer is high, the survival time of patients is short, and mutations of Wnt/beta-catenin signal channels in almost all colorectal cancers finally lead to accumulation of beta-catenin. Therefore, the content of β -catenin can be used as an auxiliary factor for clinically judging the development and prognosis of colorectal cancer, and nuclear accumulation of β -catenin can be a malignant-related marker for invasion, metastasis, poor prognosis and the like of colorectal cancer. Our experimental results show that after adding 1% of GS1108 fermentation supernatant to colon cancer cell (HCT 116) culture solution and culturing for 48 hours, the content of beta-catenin is greatly reduced, which is only 36.94% of the control without fermentation solution. At the same time, the content of phosphorylated beta-catenin (P-beta-catenin) is also obviously reduced, and the protein content is only 50.04 percent of the control. Phosphorylated β -catenin (P- β -catenin) separates from the adhesion complex and migrates into the cytoplasm, is degraded or translocated to the nucleus, triggering Wnt pathway activation. The Wnt/beta-catenin signal channel is a multifunctional channel, and the disorder of beta-catenin signal occurs in various cancers, and the Wnt/beta-catenin signal channel is involved in the regulation and control of canceration of cancers such as colorectal cancer, prostate cancer, breast cancer, malignant hematopathy and the like. Our results demonstrate that GS1108 fermentation supernatant can reduce the expression of cell adhesion factor β -catenin, thereby reducing adhesion and spread of cancer cells.
TABLE 3 influence of GS1108 fermentation supernatant on colon cancer cell beta-catenin content (gray value)
Protein of interest/reference protein | Control | GS1108 |
Beta-catenin/gapdh | 1.6243 | 0.6061 |
Phosphorylated beta-catenin (P-beta-catenin)/gapdh | 1.2770 | 0.6398 |
(2) Effect of GS1108 fermentation supernatant on apoptosis-inhibiting Gene protein content
Myeloid leukemia 1 (Mcl-1) is one of the anti-apoptotic bcl2 family members, and overexpression or amplification of Mcl1 is common in many cancer types and is therefore considered one of the most relevant oncoproteins. Our study shows that adding 1% of GS1108 fermentation supernatant to the culture medium can reduce the total MCL-1 protein content of colon cancer cells by 88.2% (Table 4), which shows that the fermentation broth has pro-cancer cell apoptosis activity. The research shows that mRNA and protein level expression of mcl1 gene subtype 1 in colon tumor tissue and corresponding side tissue is higher than that of normal group, and mcl1 subtype 1 and subtype 2 are positively correlated to malignant degree of colon cancer tumor, and can be used as one of effective diagnostic indexes for clinical evaluation of malignant degree of colon cancer.
The B cell lymphoma/leukemia-2 gene (bcl-2) also has obvious effect of inhibiting apoptosis, can inhibit cell death caused by various cytotoxins, is closely related to various cancers such as colon cancer, ovarian cancer and the like, and can enhance the resistance of cells to most cytotoxins through the overexpression of the gene. Our experiments show that the addition of 1% of GS1108 fermentation supernatant to the cell culture medium can reduce the total amount of Bcl-2 protein in colon cancer cells by 48.6% (Table 4), indicating that the fermentation supernatant has pro-apoptotic activity.
TABLE 4 influence of GS1108 fermentation supernatant on apoptosis inhibitor Gene protein content of colon cancer cells (Gray scale value)
(3) Effect of GS1108 fermentation supernatant on apoptosis factor protein content
The P62 protein is an oncogene protein, and a target gene for transcriptional regulation is involved in the processes of regulation of cell cycle, autophagy, cell proliferation, apoptosis, immortalization and the like, and plays an important role in the occurrence of a plurality of tumors. The P62 gene can help the human body to better recognize and resist exogenous antigens, thereby reducing the harm caused by infection. The P62 protein can also exert a cancer suppressing effect by promoting selective autophagy to prevent the accumulation of genotoxic and oncogenic mutations. When the P62 gene binds to an antigen, it triggers antigen-specific T cell and B cell functions. T cells secrete specific Cytokine to kill foreign pathogens, while B cells secrete specific antibodies to inhibit pathogen replication. Thus, the P62 gene can bind to an antigen, promote an immune response, and help the human body resist the foreign antigen, thereby reducing injury caused by viral infection or bacterial infection. Our experiments showed that the addition of 1% of the GS1108 fermentation supernatant to the cell culture medium greatly increased the total P62 protein of colon cancer cells, approximately 2.64 times that of the control (table 5), demonstrating the pro-apoptotic activity of the GS1108 fermentation supernatant.
Poly ADP-ribose polymerase, a poly a-p, is a DNA repair enzyme, and is a cleavage substrate for caspases (caspases) that are the core members of apoptosis, and thus plays an important role in DNA damage repair and apoptosis. PARP cleavage is considered an important indicator of apoptosis and is also commonly considered an indicator of Caspase 3 activation. PARP plays an important role in colon cancer growth and metastasis. Our results showed that the addition of 1% of the GS1108 fermentation supernatant to the medium increased the total poly-apyrase C-Parp content of colon cancer cells by 63% over the control (table 5), demonstrating the pro-apoptotic activity of the GS1108 fermentation supernatant.
TABLE 5 influence of GS1108 fermentation supernatant on the pro-apoptotic factor proteins of colon cancer cells (gray scale value)
Protein of interest/reference protein | Control | GS1108 |
P62/gapdh | 0.4673 | 1.2355 |
Poly (apyrase) C-Parp/gapdh | 1.0479 | 1.7091 |
In conclusion, the lactobacillus fermentum GS1108 strain has good adhesion to colon cancer cells, the fermentation supernatant has obvious effect of inhibiting the growth of colon cancer cells, the content of beta-catenin related to adhesion diffusion can be reduced, the content of MCL-1 and Bcl-2 proteins representing apoptosis inhibition genes can be reduced, the content of pro-apoptosis factors, namely, the clear-parp of poly-adenosine diphosphate and the P62 protein representing autophagy can be increased, and the effects of inhibiting the growth of colon cancer cells and promoting apoptosis of the lactobacillus fermentum GS1108 are proved from multiple aspects, so that the lactobacillus fermentum GS1108 strain has wide application prospect.
Example 3 adaptation and safety of Lactobacillus fermentum GS1108 to the human intestinal tract
3.1 simulation of gastric and intestinal fluid tolerance
Simulated gastric and intestinal fluids were purchased from Shanghai leaf Biotechnology Inc. The artificial gastric juice simulated liquid comprises dilute hydrochloric acid, pepsin and sodium chloride, and the final pH is 2.5; the artificial intestinal juice simulation solution comprises potassium dihydrogen phosphate and trypsin, and has a final pH of 6.8. Resuscitating lactobacillus fermentum GS1108 of strain to be detected on MRS agar plate, activating for 3 generations, and regulating initial concentration of bacterial liquid to 1×10 6 CFU/mL. 1mL of lactobacillus fermentum GS1108 bacterial liquid of the strain to be detected is inoculated into simulated gastric fluid and cultured for 3 hours at 37 ℃. After the completion of the culture, 20. Mu.L of the bacterial liquid was spread on an MRS agar plate medium, 3 replicates were set, and the culture was performed at 37℃for 24 hours, and the surface of the MRS plate after the culture was observed for colony growth. Similarly, 1mL of lactobacillus fermentum GS1108 bacteria liquid of the strain to be detected is inoculated into simulated intestinal juice, the simulated intestinal juice is cultured for 6 hours at 37 ℃, then a flat plate is coated, the culture is carried out for 24 hours at 37 ℃, and the growth condition of bacterial colonies is checked.
The simulated gastric fluid tolerance test result shows that the lactobacillus fermentum GS1108 can still grow normal colony on the MRS agar plate after being treated in the simulated gastric fluid for 3 hours; the simulated intestinal juice tolerance test result shows that the lactobacillus fermentum GS1108 can still grow normal colony on the MRS agar plate after being tolerant in the simulated intestinal juice for 6 hours; the lactobacillus fermentum GS1108 has stronger acid resistance and cholate resistance.
3.2 Lactobacillus fermentum GS1108 Strain hemolytic and antibiotic resistance
After resuscitating and activating the lactobacillus fermentum GS1108 strain for 3 generations, streaking and inoculating the strain on a Columbia blood plate, culturing the strain at 37 ℃ for 24 hours, and observing whether hemolytic rings appear around the colony to be detected, wherein the hemolytic staphylococci are used as positive control. The susceptibility of the strain to common large antibiotics was tested by a paper sheet agar diffusion method. Resuscitating lactobacillus fermentum GS1108 strain, activating for 3 passages, and regulating bacterial liquid concentration to 1×10 6 CFU/mL, and using sterile cotton swab to homogenize bacterial liquidUniformly smearing on the surface of MRS culture medium flat plate, placing drug sensitive paper sheets after room temperature for 10min, culturing at 37 ℃ for 24h, measuring the diameter of a bacteriostasis ring around each drug sensitive paper sheet by using a vernier caliper, repeating 3 times each antibiotic, and judging the drug sensitivity of the strain according to the test result by referring to the American clinical laboratory standards Committee (NCCLS), wherein the results are expressed as sensitivity (S), medium (I) and drug resistance (R).
The results of the haemolytic experiments showed that no haemolytic loops occurred around the colonies, which were more sensitive to the 5 antibiotics tested, demonstrating the safety of the lactobacillus fermentum GS1108 strain (table 4).
TABLE 6 sensitivity of Lactobacillus fermentum GS1108 Strain to 5 antibiotics
Numbering device | Tetracycline | Ampicillin (Amoxicillin) | Gentamicin | Clarithromycin | Chloramphenicol |
GS1108 | S | S | S | S | I |
Example 4 probiotic Properties of Lactobacillus fermentum GS1108 Strain
4.1 short chain fatty acid production Capacity
Preparation of fermentation liquor: after the lactobacillus fermentum GS1108 preservation strain is activated and cultured for 24 hours, 4 mu L of bacterial liquid is sucked and added into 4mL of broth culture medium, and the broth culture medium is cultured for 24 hours at 37 ℃ for standby.
Detection of short-chain fatty acids: the detection instrument was a gas chromatograph-mass spectrometer (GCMS-QP 2010 Plus) from Shimadzu corporation, and the chromatographic column was a Rtx-5 fused silica capillary column (30 m. Times.0.25 mm. Times.0.25 μm) from RESTEK (Rasteck) corporation, USA. The GC temperature program was maintained at an initial temperature of 40℃for 5min, 5℃to 150℃per minute, 10℃to 280℃per minute, and 2min. The carrier gas is high purity helium (purity > 99.999%), flow rate: 1.0mL/min. MS conditions: the ionization mode is EI; the temperature is 200 ℃, the interface temperature is 220 ℃, and the mass scanning range m/z is 33-500. Taking 4mL of fermentation liquor, adding 10 mu L of 2-ethylbutyric acid internal standard solution with the concentration of 200 mu g/mL, sampling 1 mu L of sample in a mode of 1:3 of a split flow mode, setting the solvent delay time to 0.1min, and setting the temperature of a sample inlet to 270 ℃. The concentrations of 5 short chain fatty acids (acetic acid, n-butyric acid, isobutyric acid, isovaleric acid, 2-methylbutyric acid) were calculated by the internal standard method and the measurement results are shown in Table 7.
TABLE 7 Lactobacillus fermentum GS1108 fermentation broth short chain fatty acid content (ug/mL)
Strain number | Strain name | Acetic acid | Isopentanoic acid | 2-methylbutyric acid |
GS1108 | Lactobacillus fermentum | 44.397 | 0.425 | 13.12 |
GC-MS detects the content of 5 short chain fatty acids, and the acetic acid content in the fermentation liquid of the lactobacillus fermentum GS1108 is found to be the highest, namely 44.397 mug/mL, and the fermentation liquid further comprises 2-methylbutyric acid and isovaleric acid, namely 13.12 mug/mL and 0.425 mug/mL respectively. Recent studies have found that acetic acid not only increases IgA production in the colon (immunoglobulin A is the most abundant immunoglobulin in mammals, a component that maintains mucosal surface homeostasis), but also alters IgA's ability to bind to specific microorganisms, including E.coli. Thus, acetic acid produced by intestinal microorganisms is thought to have the effect of regulating IgA production to maintain mucosal homeostasis. Butyric and isovaleric acids also have very important physiological functions.
4.2 bacteriostatic Activity against common intestinal pathogens
Escherichia coli (Escherichia coli CMCCB 44102), pseudomonas aeruginosa (Pseudomonasaeruginosa CMCCB 10104), staphylococcus aureus (Staphylococcus aureus CMCCB 50094), salmonella typhimurium (Salmonella typhimurium ATCC 14028), salmonella paratyphi B (Salmonellaparatyphi B CMCCB 50094) and Shigella dysenteriae (Shigella dysenteriae CMCCB 51105) were inoculated respectively to nutrient agar medium, recovered and activated 3 times. Sucking proper amount of trypticase liquid culture medium into a centrifuge tube, inoculating activated pathogenic bacteria into the broth culture medium, and regulating bacterial liquid concentration to 1×10 8 CFU/mL. 1mL of the mixture of the pathogenic bacteria and the broth is sucked up and added into 500mL of nutrient agar culture medium which is not solidified temporarily after sterilization (the temperature is cooled to about 40 ℃), and the mixture is fully mixed and split-packed into culture dishes according to the amount of 20mL per dish. After the culture medium is cooled and solidified, a puncher with the diameter of 6mm is used for punching holes on a flat plate, so that a pathogenic bacteria agar plate is manufactured, each plate corresponds to one strain of bacteria, and three holes are formed as repetition. Resuscitating and activating the strain to be detected, and regulating cultureThe concentration of the bacterial liquid reaches 1 multiplied by 10 8 CFU/mL. And (3) sucking 50 mu L of bacteria liquid to be detected, adding the bacteria liquid to the hole of the pathogenic bacteria agar plate, and culturing for 24 hours at 37 ℃. After incubation, the diameter of the zone of inhibition around the perforation point was measured using a vernier caliper and recorded. The above experimental procedure was performed simultaneously with the strain to be tested using the standard strain LGG as a control strain.
The fermentation broth has strong inhibitory activity on the growth of pathogenic bacteria such as escherichia coli, pseudomonas aeruginosa, staphylococcus aureus, salmonella typhimurium, salmonella paratyphi b, shigella dysenteriae and the like, and has basically equivalent effect to LGG standard strains (table 8). The microbial inoculum prepared from lactobacillus fermentum GS1108 strain can be used for preventing and controlling the pathogenic bacteria.
TABLE 8 evaluation of antibacterial Activity of Lactobacillus fermentum GS1108 Strain (diameter: mm)
4.3 antioxidant Activity of Lactobacillus fermentum GS1108 fermentation broth
Antioxidants are any substance that is effective in inhibiting the oxidation reaction of free radicals at low concentrations to counteract oxidative attack of the free radicals on human cells. The mechanism of action of the compound can be directly acting on free radicals or indirectly consuming substances which are easy to generate free radicals, so that further reaction is prevented, and the more the organism has strong oxidation resistance, the more healthy the organism is and the longer the life is. More and more studies have shown that antioxidant is an important step in preventing aging, because free radicals or oxidants break down cells and tissues, affect metabolic functions, and cause different health problems. If it is capable of eliminating excessive oxidative free radicals, it can be prevented from many diseases caused by free radicals and related to aging. Such as common cancers, arteriosclerosis, diabetes, cataracts, cardiovascular diseases, senile dementia, arthritis, etc., which are all considered to be related to free radicals.
Preparation of fermentation liquor: resuscitating and culturing lactobacillus fermentum GS1108 frozen strain for 24 hours, inoculating the strain into MRS liquid culture medium according to 2% of inoculum size, culturing for 24 hours at 37 ℃, centrifuging the bacterial liquid for 15 minutes at 4 ℃ and 4000r/min, and filtering the supernatant by a 0.22 mu m filter membrane to obtain fermentation supernatant (CFS) for freezing and storing.
Reagents and instrumentation: the total antioxidant capacity (T-AOC) detection kit (A015-1-2), the hydroxyl radical assay kit (A018-1-1), the DPPH radical scavenging capacity kit (A153-1-1) and the superoxide anion radical inhibition and generation assay kit (colorimetric method A052-1-1) are all produced by Nanjing's established bioengineering research. An ultraviolet visible spectrophotometer (UV 752N type), manufactured by Shanghai you family instruments and meters limited; the antioxidant capacity of the fermentation broth was measured by Chengdu Biotechnology Co.
Total antioxidant capacity (Total antioxidant capacity, T-AOC) refers to the total antioxidant level of the various antioxidant substances make up. The research on antioxidation can effectively overcome the harm brought by the antioxidation, so that the enterprises of the antioxidation healthcare products and cosmetics are one of main research and development directions and one of the most important functional requirements of the market. Many antioxidant substances can reduce Fe3+ into Fe2+, and the Fe+ can form a firm complex with phenanthrene substances, and the oxidation resistance of the Fe+ can be measured by colorimetry. Absorbance was measured using a wavelength 520nm,1cm optical path, double distilled water zeroed. The specific steps are carried out according to the instruction of a total antioxidant capacity (T-AOC) detection kit. The measurement results of the total antioxidant capacity of the fermentation broth of lactobacillus fermentum GS1108 are shown in Table 9, and the total antioxidant capacity of the fermentation broth of Pediococcus pentosaceus TE0307 is 39.10+/-0.65U/mL, which indicates that the fermentation broth of GS1108 has better antioxidant capacity.
Ability to inhibit hydroxyl radicals: one of the hydroxyl radical active oxygen has extremely strong electron-obtaining ability, namely, has extremely strong oxidizing ability. Hydroxyl radicals kill red blood cells and degrade DNA, cell membranes and polysaccharide compounds. Fenton (Fenton) reaction is the most common chemical reaction generating hydroxyl radicals, H 2 O 2 The amount of (2) is proportional to the amount of hydroxyl radicals generated by the Fenton reaction, and after the electron acceptor is given, the color is developed by the Griess reagent to form a red substance, and the color is proportional to the amount of the hydroxyl radicals. The absorbance was measured at 550nm, exactly as per the instructions. Computational formulas such asThe following steps:
ability to inhibit hydroxyl radicals (U/mL) = (a) Control -A Measurement )/(A Standard of -A Blank space )×C Standard of ×(1/V Sample )×N
In the formula, the standard concentration is 8.824mmol/L; v sample: sampling amount, 0.2mL; n: dilution fold before sample testing.
The measurement results are shown in Table 8, and the fermentation liquid of the lactobacillus fermentum GS1108 has stronger capability of inhibiting hydroxyl radicals, namely 3150.54 +/-111.27U/mL.
DPPH radical scavenging ability: DPPH is also called 1, 1-diphenyl-2-trinitrophenylhydrazine, and is a very stable free radical of nitrogen center. Since DPPH free radical has single electron, there is a strong absorption at 517nm, its alcohol solution is purple, when free radical scavenger exists, its absorption gradually disappears due to pairing with its single electron, the light color is presented, therefore, the DPPH scavenging ability in the sample can be quantitatively analyzed. According to the instruction of the kit, one standard substance powder is dissolved by adding 2mL of absolute methanol to obtain 0.5mg/mL (Trolox) standard application liquid, and then the standard substance powder is diluted into 5 mug/mL, 10 mug/mL, 15 mug/mL, 20 mug/mL and 25 mug/mL respectively by using absolute methanol, the light path with the wavelength of 517nm and 1cm is zeroed by using absolute ethanol, and the absorbance of each tube is measured to prepare a standard curve.
DPPH radical clearance (%) = (1- (assay-a control)/(a blank) ×100%
The DPPH radical scavenging capacity of the samples was expressed as the amount corresponding to the antioxidant Trolox calculated from the standard curve. Fermentation broth samples DPPH free radical scavenging capacity (μg Trolox/mL) =substituted into the standard curve to give a concentration corresponding to Trolox x dilution factor. The DPPH radical scavenging ability measurement results of the fermentation broth of the lactobacillus fermentum GS1108 are shown in Table 9, and the DPPH radical scavenging ability 177.20 + -1.42 mug Trolox/mL of the fermentation broth of the lactobacillus fermentum GS1108 shows that the fermentation broth of the lactobacillus fermentum GS1108 has better DPPH radical scavenging ability.
Resistance to superoxide anions: the superoxide anion free radical is used as a free radical generated in the metabolic process of organisms, and can attack biological macromolecules such as lipid, protein, nucleic acid, polyunsaturated fatty acid and the like, so that the biological macromolecules are crosslinked or broken, the cell structure and the function are damaged, and the superoxide anion free radical has a close relationship with the aging and pathological changes of the organisms. The experiment simulates a xanthine and xanthine oxidase reaction system in an organism to generate superoxide anion free radicals, an electron transfer substance and a Gress's color developing agent are added to enable the reaction system to be purple red, a spectrophotometer is used for measuring the absorbance of the reaction system, when a tested sample contains a superoxide anion free radical inhibitor, the absorbance of a measuring tube is lower than that of a control tube in colorimetric process, and the inhibition capacity of a tested object to the superoxide anion free radicals can be calculated by taking vitamin C as a standard. When in measurement, a 1cm optical path cuvette is used, double distilled water is used for zeroing, and color comparison is carried out at the wavelength of 550 nm.
Superoxide anion resistance (U/L) = (a) Control -A Measurement )/(A Control -A Standard of )×C Standard of ×1000×N
In the reaction system, the change value of the superoxide anion radical inhibited by the reaction of each liter of fermentation broth at 37 ℃ for 40 minutes corresponds to 1mg of the superoxide anion radical inhibited by vitamin C, and the change value is one activity unit. As shown in Table 8 below, the measurement results of the anti-superoxide anion capacity of the fermentation broth of Lactobacillus fermentum GS1108 show that the inhibition capacity of the fermentation broth of Lactobacillus fermentum GS1108 against superoxide anion radicals is 785.47 + -7.56 (U/L), which indicates that the inhibition capacity of the fermentation broth of Lactobacillus fermentum GS1108 against superoxide anion radicals is stronger.
TABLE 9 antioxidant capacity of Lactobacillus fermentum GS1108 fermentation broth
In conclusion, the GS1108 fermentation liquor has strong antioxidant capacity and potential application value in the field of functional foods, including being used for improving the health level of human bodies.
While the present invention has been described in detail through the foregoing description of the preferred embodiment, it should be understood that the foregoing description is not to be considered as limiting the invention. Many modifications and substitutions of the present invention will become apparent to those of ordinary skill in the art upon reading the foregoing. Accordingly, the scope of the invention should be limited only by the attached claims.
Claims (10)
1. A strain of lactobacillus fermentum (Lactobacillus fermentans) GS1108 is preserved in China general microbiological culture Collection center (CGMCC) with the preservation number of 27395 in the year 2023 and the month 5 and the day 22.
2. Use of lactobacillus fermentum (Lactobacillus fermentans) GS1108 according to claim 1 for the manufacture of an anti-colon cancer medicament or an anti-colon cancer adjuvant.
3. Use of lactobacillus fermentum (Lactobacillus fermentans) GS1108 of claim 1 for inhibiting escherichia coli, pseudomonas aeruginosa, staphylococcus aureus, salmonella typhimurium, salmonella paratyphi b or shigella dysenteriae for non-disease treatment purposes.
4. Use of lactobacillus fermentum (Lactobacillus fermentans) GS1108 according to claim 1 for the manufacture of a medicament for the treatment of a disease caused by escherichia coli, pseudomonas aeruginosa, staphylococcus aureus, salmonella typhimurium, salmonella paratyphi b or shigella dysenteriae.
5. Use of lactobacillus fermentum (Lactobacillus fermentans) GS1108 according to claim 1 for the preparation of a medicament with antioxidant function.
6. Use of lactobacillus fermentum (Lactobacillus fermentans) GS1108 according to claim 1 in a functional food for modulating the intestinal flora of a human or animal.
7. An anti-colon cancer drug or an anti-colon cancer adjuvant comprising lactobacillus fermentum (Lactobacillus fermentans) GS1108 of claim 1.
8. An antioxidant drug comprising lactobacillus fermentum (Lactobacillus fermentans) GS1108 of claim 1.
9. A functional food comprising lactobacillus fermentum (Lactobacillus fermentans) GS1108 of claim 1.
10. Use of lactobacillus fermentum (Lactobacillus fermentans) GS1108 in combination with 5-fluorouracil or oxaliplatin according to claim 1 for the preparation of a medicament for the treatment of colon cancer.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310899300.7A CN116836879B (en) | 2023-07-21 | 2023-07-21 | Lactobacillus fermentum with colon cancer cell growth inhibition effect and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310899300.7A CN116836879B (en) | 2023-07-21 | 2023-07-21 | Lactobacillus fermentum with colon cancer cell growth inhibition effect and application thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN116836879A true CN116836879A (en) | 2023-10-03 |
CN116836879B CN116836879B (en) | 2024-01-23 |
Family
ID=88174275
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310899300.7A Active CN116836879B (en) | 2023-07-21 | 2023-07-21 | Lactobacillus fermentum with colon cancer cell growth inhibition effect and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116836879B (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115747111A (en) * | 2022-11-25 | 2023-03-07 | 四川大学 | Pediococcus pentosaceus and application thereof |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101995328B1 (en) * | 2018-12-10 | 2019-07-02 | 한국식품연구원 | Lactobacillus fermentum WiKim0102 having anti-cancer activity and composition for comprising the same |
CN113234612A (en) * | 2021-02-05 | 2021-08-10 | 重庆第二师范学院 | Lactobacillus fermentum ZS40 having preventive effect on colitis |
CN114191490A (en) * | 2022-01-28 | 2022-03-18 | 善恩康生物科技(苏州)有限公司 | Lactobacillus fermentum and application of lactobacillus fermentum product in oxidation resistance and tumor resistance |
CN114874951A (en) * | 2022-06-14 | 2022-08-09 | 内蒙古一康健康发展有限责任公司 | Novel lactobacillus rhamnosus strain and application thereof |
WO2022231178A1 (en) * | 2021-04-27 | 2022-11-03 | (주)에이투젠 | Novel lactobacillus fermentum atg-v5 strain, or composition for enhancing immunity, comprising same |
-
2023
- 2023-07-21 CN CN202310899300.7A patent/CN116836879B/en active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101995328B1 (en) * | 2018-12-10 | 2019-07-02 | 한국식품연구원 | Lactobacillus fermentum WiKim0102 having anti-cancer activity and composition for comprising the same |
CN113234612A (en) * | 2021-02-05 | 2021-08-10 | 重庆第二师范学院 | Lactobacillus fermentum ZS40 having preventive effect on colitis |
WO2022231178A1 (en) * | 2021-04-27 | 2022-11-03 | (주)에이투젠 | Novel lactobacillus fermentum atg-v5 strain, or composition for enhancing immunity, comprising same |
CN114191490A (en) * | 2022-01-28 | 2022-03-18 | 善恩康生物科技(苏州)有限公司 | Lactobacillus fermentum and application of lactobacillus fermentum product in oxidation resistance and tumor resistance |
CN114874951A (en) * | 2022-06-14 | 2022-08-09 | 内蒙古一康健康发展有限责任公司 | Novel lactobacillus rhamnosus strain and application thereof |
Non-Patent Citations (3)
Title |
---|
CC TSAI等: "Lactobacillus spp. inhibits the growth of HCT-116 and reduces IL-8 secretion by Salmonella typhimurium-infected HCT-116 colorectal carcinoma cells", INTERNATIONAL JOURNAL OF FOOD STUDIES, vol. 11, no. 2 * |
LIU JIA等: "Effect of Lactobacillus fermentum ZS40 on the NF-kB signaling pathway in an azomethane-dextran sulfate sodium-induced colon cancer mouse model", FRONTIERS IN MICROBIOLOGY, vol. 13 * |
熊世进;高文功;杨菲菲;赵雪婷;秦小彤;杜同浩;熊涛;: "六株人源益生菌的表面性质与黏附性能研究", 食品工业科技, no. 09 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115747111A (en) * | 2022-11-25 | 2023-03-07 | 四川大学 | Pediococcus pentosaceus and application thereof |
CN115747111B (en) * | 2022-11-25 | 2023-12-12 | 四川大学 | Pediococcus pentosaceus and application thereof |
Also Published As
Publication number | Publication date |
---|---|
CN116836879B (en) | 2024-01-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Lapenda et al. | Antimicrobial activity of prodigiosin isolated from Serratia marcescens UFPEDA 398 | |
CN115786198B (en) | Lactobacillus paracasei and application thereof | |
CN116836879B (en) | Lactobacillus fermentum with colon cancer cell growth inhibition effect and application thereof | |
CN115747111B (en) | Pediococcus pentosaceus and application thereof | |
CN116121146B (en) | Pediococcus pentosaceus with relatively high lactic acid production capacity and application thereof | |
CN115851500B (en) | Lactobacillus plantarum and application thereof | |
CN111778180B (en) | Breast milk source lactobacillus plantarum and application thereof | |
CN110023484B (en) | Bifidobacterium pseudocatenulatum as well as culture method and application thereof | |
CN113122485A (en) | Lactobacillus plantarum HNU082 with antagonistic effect and application thereof | |
CN113604410B (en) | Lactobacillus plantarum YT013 and application thereof | |
CN111000244A (en) | Lactobacillus casei capable of improving intestinal health and application thereof | |
Wang et al. | Fungi with potential probiotic properties isolated from Fuzhuan brick tea | |
CN116769655A (en) | Streptococcus salivarius thermophilus JIAN+ and application thereof | |
Saffar et al. | Analyzing of colorectal cancerrelated genes and microRNAs expression profiles in response to probiotics Lactobacillus acidophilus and Saccharomyces cerevisiae in colon cancer cell lines | |
CN116463264B (en) | Lactobacillus plantarum with colon cancer cell growth inhibition effect and application thereof | |
WO2008064521A1 (en) | Lactobacillus fermentum cms-h002 and use thereof | |
CN116948916A (en) | Lactobacillus casei and application thereof | |
CN117903980A (en) | Enterococcus hai and application thereof | |
CN117801994A (en) | Lactobacillus gasseri HP2C12 and application thereof | |
CN117866853A (en) | Pediococcus acidilactici with cervical cancer cell apoptosis promoting effect and application thereof | |
Kocabay | Evaluation of probiotic properties of Levilactobacillus brevis isolated from hawthorn vinegar | |
CN116622568A (en) | Lactobacillus harbini P1-1 and application thereof | |
CN113373084B (en) | Antibacterial and exopolysaccharide-producing lactobacillus curvatus and application thereof | |
Jaiswal et al. | Microbiological diversity of fermented food Bhaati Jaanr and its antioxidant and anti-inflammatory properties: Effect against colon cancer | |
CN115044504B (en) | Enterococcus faecalis YZ-1 and probiotic application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |